查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1521976

全球精神分裂症藥物市場：按分銷管道、治療類別、國家和公司分析（2024-2032）

Global Schizophrenia Drugs Market Report by Distribution Channel Treatment Therapeutic Class Countries and Company Analysis, 2024-2032
出版日期: | 出版商: Renub Research | 英文 165 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

精神分裂症藥物市場分析

全球精神分裂症藥物市場規模預計將從 2030 年的 74.331 億美元增至 2032 年的 101.324 億美元以上，2024 年至 2032 年複合年增長率為 3.50%。這種增長是由於精神分裂症盛行率的增加、藥物處方的創新以及公眾對精神疾病的瞭解的提高。

精神分裂症治療藥物市場前景

精神分裂症是一種急性和慢性精神疾病，會改變患者的行為。症狀包括看到或聽到不真實的事物、有奇怪的信念、難以做出決定或表達情緒。然而，研究表明，遺傳、胎兒發育期間發生的事件（例如接觸病毒、營養不良、壓力情況等）以及大腦的內容和線路等因素的結合也可能是性別的原因。

精神分裂症主要採用抗精神病藥物治療，大致分為兩類：第一代（典型）和第二代（非典型）。這兩類藥物作用於大腦中的神經傳導物質以減輕症狀。精神分裂症患者需要與他們的醫療保健提供者互動，以找出副作用最小的最佳藥物。因此，精神分裂症的有效治療和患者生活品質的改善取決於治療和社會支持。

精神分裂症治療藥物市場的驅動因素

公營和私營部門的舉措

與精神健康相關的政府政策和精神分裂症藥物的補貼投資產生了巨大的影響。市場驅動因素包括政府對精神健康服務、基礎設施發展、醫療改革和精神疾病人格解體的政策。額外的資金是推動藥物開發創新和改善患者治療效果的關鍵。以健康為中心的廣告、學校和其他機構的特殊計畫所創造的意識確保人們為自己尋求治療和抗精神病藥物。這些政府措施有助於使精神分裂症更容易控制，加強治療方法和精神分裂症藥物市場。

改善診斷和治療設施

更好的診斷工具和治療中心的可用性也有助於精神分裂症的早期診斷，以便及時採取適當的干預措施。CT 掃瞄、MRI、實驗室檢查（包括基因鑑定）和增強篩檢技術等現代診斷方法可確保早期發現疾病，以便及早治療。綜合護理設施提供各種服務，包括藥物治療、心理治療和服務支持，並被發現可以帶來卓越的患者體驗。這是因為透過早期診斷和早期干預，可以更好地控制疾病症狀，從而改善大多數患者的生活方式並遵守醫生的建議。被診斷出患有精神分裂症的患者越來越多地透過使用抗精神病藥物進行治療，從而推動了精神分裂症治療藥物的市場。

精神分裂症盛行率上升

世界各地的人們罹患精神分裂症的比率比以往任何時候都高。因此，需要更有效的藥物治療。隨著被診斷出患有這種慢性精神疾病的患者數量增加，對新型有效抗精神病藥物的需求也在增加。增加人們獲取有關精神分裂症及其症狀的資訊將改善就醫行為。提高心理健康意識和更好地獲得醫療服務也促成了這種情況。隨著對精神分裂症患者評估的增加，對改善患者生活品質的新藥和控制症狀的優質治療的需求不斷增加。

亞太地區精神分裂症藥物市場

目前，由於心理健康意識的提高和精神分裂症的高盛行率，亞太地區的精神分裂症治療市場正在蓬勃發展。中國、印度、日本等國人口眾多、醫療設施發達，並做出了重要貢獻。透過政府措施和增加對醫療保健行業的投資來改善心理健康服務，這對市場成長產生了積極影響。然而，遠離城市地區的恥辱和缺乏足夠的精神衛生設施等問題仍然存在。不過，一些分析師認為，新藥開發領域的持續研究和對心理健康服務的關注可能會促使市場穩定成長。

該報告審視了全球精神分裂症治療藥物市場，並提供市場成長驅動因素和課題、市場佔有率分析、公司分析等。

目錄

第1章 簡介

第2章 研究方法

第3章 執行摘要

第4章 市場動態

  • 增長動力
  • 任務

第5章 全球精神分裂症治療藥物市場

第6章 市佔率分析

  • 透過治療
  • 按治療類別
  • 按分銷渠道
  • 按國家

第7章 治療

  • 口服
  • 注射

第8章 治療階級

  • 第二代
  • 第三代
  • 其他

第9章 通路

  • 醫院藥房
  • 零售藥店
  • 網上藥店

第10章 國家

  • 美洲
    • 美國
    • 加拿大
    • 墨西哥
    • 巴西
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
  • 中東/非洲
    • 南非
    • 阿拉伯聯合酋長國
  • 其他地區

第11章 公司分析

  • H. Lundbeck A/S
  • Pfizer Inc.
  • AbbVie
  • AstraZeneca
  • Bristol Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis AG
  • Takeda Pharmaceuticals
簡介目錄

Schizophrenia Drugs Market Analysis

Global schizophrenia drugs market will increase from US$ 7,433.1 million in 2030 to over US$ 10,132.4 million by 2032 with a CAGR of 3.50% from 2024 to 2032. This growth is as a result of the growing incidences of schizophrenia, innovations in drug formulation, and enhancement of people's knowledge on mental illnesses.

Schizophrenia Drugs Market Outlook

Schizophrenia is an acute and chronic mental disorder that patient behavior. It results in different manifestations which include sees or hears things that are not real, has strange beliefs and has issues with decision making and demonstrating feelings. Nonetheless, studies show that it may be a combination of heredity, events that occur while the fetus is still developing (such as, being exposed to viruses, malnutrition or stressful situations), and the brain's contents and wiring that may also be attributed to it.

Schizophrenia is primarily treated with antipsychotic medications, which come in two main types: first generation (typical) and second generation (atypical). These two types of drugs function in that they tend to affect neurotransmitters within the brain in order to help to reduce the symptoms. Schizophrenia patients should have a mutual relationship with their health care givers with an aim of identifying the best drug that could be administered with minimal side effects. Thus, the effective treatment of schizophrenia and the upshot of the patients' quality of life depend on therapy and social support.

Driving Factors in the Schizophrenia Drugs Market

Government and Private Sector Initiatives:

Mental health related government policies and grant investment on schizophrenia drug have a very prominent influence. The factors driving the market include the government policies towards mental health services, development of infrastructure, healthcare reforms, and destigmatization of mental illness. Additional funding is the key to spurring innovation in the development of new medications and improving outcomes for patients. Awareness created by health-focused commercials, special programs in schools, and other institutions ensure that individuals seek treatment and seek antipsychotic drugs for themselves. Such governmental initiatives do make the environment more conducive toward managing schizophrenia and contribute to enhancing the treatment approaches and the market for the schizophrenia medications.

Improved Diagnostic and Treatment Facilities:

Availability of better diagnostic tools and treatment centers also helps in early diagnosis of schizophrenia and a proper intervention is taken on time. Modern diagnostic methods such as CT scans, MRIs, laboratory tests including gene identification and enhanced techniques of screening, make sure that the disorder is detected at a primary stage so as to be accorded an early treatment. It is observed that comprehensive care facility output a range of services that include medication, psychotherapy and service support leading to the improved patient's experiences. This is because symptoms of the disease are managed well through early diagnosis and intervention, hence lifestyles of most patients are enhanced, and they also comply with recommendations from practitioners. The patients diagnosed with schizophrenic disorders are encouraged to continue with the treatment through use of antipsychotic drugs thus promoting the market of schizophrenia drugs.

Rising Prevalence of Schizophrenia:

People around the world are developing schizophrenia at a higher rate than in the past; thus, there is needed a more effective medication solution for the disease. With patients diagnosed with this chronic mental disorder increasing in number, the requirement for new and effective antipsychotic drugs is also increasing. Higher incidence of public access to information on schizophrenia and its manifestation in people's lives improves healthcare seeking behavior. Raising awareness of mental health, and having access to better healthcare services also contributes to this scenario. Thus, an increase in the appreciation of schizophrenic patients results in the growth of demand for new drugs and improved treatments for controlling symptoms so as to enhance the client's quality of life.

Asia Pacific Schizophrenia Drugs Market

Currently, the Asia Pacific market for schizophrenia drug is trending due to the awareness of mental health and high prevalence of schizophrenia in the markets. Countries such as china India and Japan are indispensable contributors owning to their huge populace and enhancing health facility amenities. There is an emphasis on the improvement of mental health services through governmental actions and raising investments into the healthcare segment, which positively influence market growth. There are new and advanced antipsychotic drugs to help with the unmet medical requirements; however, there are continued problems like prejudice and lack of appropriate mental health facilities far from urban regions. However, some analysts agree that the market is likely to expand steadily due to continued research in the field of development of new medicines and the focus on mental health services.

Global Schizophrenia Drugs Company Analysis:

Schizophrenia Drugs market is stable and growing, leading companies like H Lundbeck, Pfizer Inc, AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Takeda Pharmaceuticals were actively participating in the market and continuously contributing in the development of the market.

Global Schizophrenia Drugs Company News:

March 2022: AbbVie and Gedeon Richter entered a partnership to develop and market dopamine receptor modulators for the potential treatment of neuropsychiatric disorders.

February 2022: Vanderbilt University partnered with Neumora Therapeutics to develop precision treatments for brain illnesses by combining data science and neuroscience, focusing on neuropsychiatric diseases like schizophrenia.

Treatment -Market Breakup in 2 Viewpoints -

1. Oral

2. Injectable

Therapeutic Class - Market Breakup in 3 Viewpoints -

1. Second Generation

2. Third Generation

3. Others

Distribution Channel - Market Breakup in 4 Viewpoints -

1. Hospital Pharmacies

2. Retail Pharmacies

3. Online Pharmacies

Geography - Market Breakup of 18 countries -

  • North America

United States

Canada

Mexico

Brazil

  • Europe

United Kingdom

Germany

France

Italy

Spain

Netherlands

  • Asia Pacific

China

Japan

India

South Korea

Australia

  • Middle East & Africa

South Africa

United Arab Emirates

  • Rest of the World

Company Insights:

  • Overview
  • Business Strategy
  • Product Portfolio
  • Financial Insight

Key Players Analysis:

1. H Lundbeck

2. Pfizer Inc.

3. AbbVie

4. AstraZeneca

5. Bristol Myers Squibb

6. Eli Lilly

7. GlaxoSmithKline

8. Johnson & Johnson

9. Novartis AG

10. Takeda Pharmaceuticals

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Schizophrenia Drugs Market

6. Market Share Analysis

  • 6.1 By Treatment
  • 6.2 By Therapeutic Class
  • 6.3 By Distribution Channel
  • 6.4 By Country

7. Treatment

  • 7.1 Oral
  • 7.2 Injectable

8. Therapeutic Class

  • 8.1 Second Generation
  • 8.2 Third Generation
  • 8.3 Others

9. Distribution Channel

  • 9.1 Hospital Pharmacies
  • 9.2 Retail Pharmacies
  • 9.3 Online Pharmacies

10. Country

  • 10.1 Americas
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
    • 10.1.4 Brazil
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
  • 10.4 Middle East & Africa
    • 10.4.1 South Africa
    • 10.4.2 United Arab Emirates
  • 10.5 Rest of the World

11. Company Analysis

  • 11.1 H. Lundbeck A/S
    • 11.1.1 Overview
    • 11.1.2 Business Strategy
    • 11.1.3 Product Portfolio
    • 11.1.4 Financial Insight
  • 11.2 Pfizer Inc.
    • 11.2.1 Overview
    • 11.2.2 Business Strategy
    • 11.2.3 Product Portfolio
    • 11.2.4 Financial Insight
  • 11.3 AbbVie
    • 11.3.1 Overview
    • 11.3.2 Business Strategy
    • 11.3.3 Product Portfolio
    • 11.3.4 Financial Insight
  • 11.4 AstraZeneca
    • 11.4.1 Overview
    • 11.4.2 Business Strategy
    • 11.4.3 Product Portfolio
    • 11.4.4 Financial Insight
  • 11.5 Bristol Myers Squibb
    • 11.5.1 Overview
    • 11.5.2 Business Strategy
    • 11.5.3 Product Portfolio
    • 11.5.4 Financial Insight
  • 11.6 Eli Lilly
    • 11.6.1 Overview
    • 11.6.2 Business Strategy
    • 11.6.3 Product Portfolio
    • 11.6.4 Financial Insight
  • 11.7 GlaxoSmithKline
    • 11.7.1 Overview
    • 11.7.2 Business Strategy
    • 11.7.3 Product Portfolio
    • 11.7.4 Financial Insight
  • 11.8 Johnson & Johnson
    • 11.8.1 Overview
    • 11.8.2 Business Strategy
    • 11.8.3 Product Portfolio
    • 11.8.4 Financial Insight
  • 11.9 Novartis AG
    • 11.9.1 Overview
    • 11.9.2 Business Strategy
    • 11.9.3 Product Portfolio
    • 11.9.4 Financial Insight
  • 11.10 Takeda Pharmaceuticals
    • 11.10.1 Overview
    • 11.10.2 Business Strategy
    • 11.10.3 Product Portfolio
    • 11.10.4 Financial Insight